[HTML][HTML] Antiparkinson prodrugs
A Di Stefano, P Sozio, LS Cerasa - Molecules, 2008 - mdpi.com
Parkinson's disease (PD) is a progressive, neurodegenerative disorder which involves the
loss of dopaminergic neurons of the substantia nigra pars compacta. Current therapy is …
loss of dopaminergic neurons of the substantia nigra pars compacta. Current therapy is …
[PDF][PDF] Antiparkinson Prodrugs
A Di Stefano, P Sozio, LS Cerasa - Molecules, 2008 - researchgate.net
Parkinson's disease (PD) is a progressive, neurodegenerative disorder which involves the
loss of dopaminergic neurons of the substantia nigra pars compacta. Current therapy is …
loss of dopaminergic neurons of the substantia nigra pars compacta. Current therapy is …
[引用][C] Antiparkinson Prodrugs
A DI STEFANO, P Sozio, LS Cerasa - MOLECULES, 2008 - ricerca.unich.it
Antiparkinson Prodrugs IRIS IRIS Home Sfoglia Macrotipologie & tipologie Autore Titolo Riviste
Serie IT Italiano Italiano English English LOGIN 1.IRIS 2.Catalogo Ricerca 3.1 Contributo su …
Serie IT Italiano Italiano English English LOGIN 1.IRIS 2.Catalogo Ricerca 3.1 Contributo su …
[PDF][PDF] Antiparkinson Prodrugs
A Di Stefano, P Sozio, LS Cerasa - Molecules, 2008 - mdpi.org
Parkinson's disease (PD) is a progressive, neurodegenerative disorder which involves the
loss of dopaminergic neurons of the substantia nigra pars compacta. Current therapy is …
loss of dopaminergic neurons of the substantia nigra pars compacta. Current therapy is …
[PDF][PDF] Antiparkinson Prodrugs
A Di Stefano, P Sozio, LS Cerasa - Molecules, 2008 - mdpi.org
Parkinson's disease (PD) is a progressive, neurodegenerative disorder which involves the
loss of dopaminergic neurons of the substantia nigra pars compacta. Current therapy is …
loss of dopaminergic neurons of the substantia nigra pars compacta. Current therapy is …
[HTML][HTML] Antiparkinson Prodrugs
A Di Stefano, P Sozio, LS Cerasa - Molecules, 2008 - ncbi.nlm.nih.gov
Parkinson's disease (PD) is a progressive, neurodegenerative disorder which involves the
loss of dopaminergic neurons of the substantia nigra pars compacta. Current therapy is …
loss of dopaminergic neurons of the substantia nigra pars compacta. Current therapy is …
Antiparkinson prodrugs.
A Di Stefano, P Sozio, LS Cerasa - Molecules (Basel, Switzerland), 2008 - europepmc.org
Parkinson's disease (PD) is a progressive, neurodegenerative disorder which involves the
loss of dopaminergic neurons of the substantia nigra pars compacta. Current therapy is …
loss of dopaminergic neurons of the substantia nigra pars compacta. Current therapy is …
[PDF][PDF] Antiparkinson Prodrugs
A Di Stefano, P Sozio, LS Cerasa - Molecules, 2008 - Citeseer
Parkinson's disease (PD) is a progressive, neurodegenerative disorder which involves the
loss of dopaminergic neurons of the substantia nigra pars compacta. Current therapy is …
loss of dopaminergic neurons of the substantia nigra pars compacta. Current therapy is …
Antiparkinson Prodrugs
A Di Stefano, P Sozio, LS Cerasa - Molecules, 2008 - search.proquest.com
Parkinsons disease (PD) is a progressive, neurodegenerative disorder whichinvolves the
loss of dopaminergic neurons of the substantia nigra pars compacta. Currenttherapy is …
loss of dopaminergic neurons of the substantia nigra pars compacta. Currenttherapy is …
Antiparkinson prodrugs
A Di Stefano, P Sozio… - Molecules (Basel …, 2008 - pubmed.ncbi.nlm.nih.gov
Parkinson's disease (PD) is a progressive, neurodegenerative disorder which involves the
loss of dopaminergic neurons of the substantia nigra pars compacta. Current therapy is …
loss of dopaminergic neurons of the substantia nigra pars compacta. Current therapy is …